Should I add short‑term hydroxyzine for two weeks while continuing bupropion 150 mg extended‑release to manage anxiety and insomnia?

Short-Term Hydroxyzine Addition: Not Recommended

I do not recommend adding hydroxyzine for 2 weeks to your current bupropion 150 mg extended-release regimen for anxiety and insomnia. Instead, optimize your bupropion dose first, as the evidence shows bupropion itself effectively treats both anxiety and insomnia in depression when dosed appropriately.

Why Bupropion Optimization is the Better First Step

Bupropion's Proven Efficacy for Your Symptoms

Bupropion extended-release at therapeutic doses (300-450 mg/day) has demonstrated significant improvement in both anxiety and insomnia domains in patients with major depressive disorder 1. Your current 150 mg dose is subtherapeutic—you're taking half the minimum effective dose. The FDA label indicates that insomnia occurs in 11-20% of patients on bupropion 2, but this is often dose-dependent and transient, while the therapeutic benefits for anxiety and sleep improve at adequate dosing 1.

Key evidence: A 2025 systematic review found that bupropion provides clinically relevant improvement in anxiety symptoms in adults with MDD, with generally comparable efficacy to SSRIs 3. Another controlled trial specifically demonstrated that bupropion XL significantly reduced both insomnia domain scores (p=0.023) and anxiety symptoms in depressed patients 1.

Problems with Adding Hydroxyzine

The 2017 AASM insomnia guideline explicitly states that over-the-counter antihistamine sleeping aids (which includes hydroxyzine) are not recommended due to lack of demonstrated efficacy and safety concerns 4. While hydroxyzine has shown some efficacy for generalized anxiety disorder 5, 6, the evidence for insomnia is weak:

• A 2023 systematic review of hydroxyzine for sleep found only mixed efficacy across sleep measures, with most studies failing to report safety outcomes 7
• The most common side effect is drowsiness (28% vs 14% placebo), which paradoxically can worsen daytime function 6
• Hydroxyzine has alpha-adrenergic antagonism that can cause serious adverse effects when combined with other medications 8

Recommended Treatment Algorithm

Step 1: Increase Bupropion Dose (Weeks 1-2)

• Increase bupropion XL to 300 mg daily
• Monitor for anxiety improvement within 1-2 weeks 9
• Common side effects at this dose: dry mouth, mild insomnia (typically transient) 2

Step 2: Assess Response (Week 6-8)

If inadequate response after 6-8 weeks at 300 mg 9:

• Consider increasing to 450 mg daily (maximum FDA-approved dose)
• OR switch to a different antidepressant class (SSRI/SNRI) if anxiety remains severe

Step 3: Address Persistent Insomnia (If Needed)

If insomnia persists despite adequate antidepressant dosing:

• First-line: Cognitive behavioral therapy for insomnia (CBT-I) 4
• Second-line: Short/intermediate-acting benzodiazepine receptor agonists or ramelteon 4
• Not hydroxyzine due to lack of evidence 4

Critical Caveats

Monitor closely for worsening symptoms: The American College of Physicians guideline mandates assessment within 1-2 weeks of any antidepressant initiation or dose change, with particular attention to suicidal ideation, agitation, or unusual behavioral changes 9.

Bupropion's seizure risk: While generally low (0.1% at doses ≤300 mg/day), risk increases at higher doses. Avoid if you have seizure history, eating disorders, or abrupt alcohol/benzodiazepine discontinuation 2.

Sexual function advantage: Unlike SSRIs, bupropion has significantly lower rates of sexual dysfunction 9, making it preferable if this is a concern.

Why This Approach Prioritizes Outcomes

This recommendation prioritizes morbidity and mortality by:

1. Avoiding polypharmacy with an agent (hydroxyzine) that lacks strong evidence for your indication
2. Optimizing a proven medication (bupropion) that addresses both your anxiety and depression
3. Reducing risk of drug interactions and side effects from unnecessary combination therapy
4. Following guideline-concordant care that emphasizes monotherapy optimization before adding agents 4, 9

The evidence clearly shows that 38% of patients don't respond to initial antidepressant doses, and 54% don't achieve remission 9—but this is often because doses remain subtherapeutic. Increase your bupropion first 9.